Cardiovascular safety of acute recombinant human thyrotropin administration to patients monitored for differentiated thyroid cancer

Bernadette Biondi, Emiliano A. Palmieri, Loredana Pagano, Michele Klain, Giovanna Scherillo, Marco Salvatore, Gianfranco Fenzi, Gaetano Lombardi, Serafino Fazio

Research output: Contribution to journalArticlepeer-review

Abstract

Eleven patients who had undergone total thyroidectomy for differentiated thyroid cancer and who were on chronic TSH-suppressive therapy with levothyroxine (L-T4), underwent 24-h Holter electrocardiogram and Doppler-echocardiography before and after acute recombinant human TSH (rhTSH) administration for disease staging. The treatment, which was generally well tolerated, did not affect circulating thyroid hormones levels, nor did it have measurable effects on heart rate, rhythm, left ventricular morphology, or systo-diastolic function. Notably, arterial blood pressure tended to be slightly reduced after rhTSH administration, although in no instance did the patients become frankly symptomatic. Our data demonstrate that rhTSH does not alter cardiovascular function acutely. Consequently, it can safely be used in the routine staging of patients affected by differentiated thyroid cancer.

Original languageEnglish
Pages (from-to)211-214
Number of pages4
JournalJournal of Clinical Endocrinology and Metabolism
Volume88
Issue number1
DOIs
Publication statusPublished - Jan 1 2003

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Cardiovascular safety of acute recombinant human thyrotropin administration to patients monitored for differentiated thyroid cancer'. Together they form a unique fingerprint.

Cite this